scholarly journals Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma

2015 ◽  
Vol 106 (8) ◽  
pp. 1016-1022 ◽  
Author(s):  
Keisuke Nakao ◽  
Shinji Tanaka ◽  
Tomoya Miura ◽  
Kota Sato ◽  
Satoshi Matsumura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals SORAFENIB INDUCED ACNEIFORM ERUPTIONS: A CASE REPORT

2017 ◽  
Vol 10 (4) ◽  
pp. 6 ◽  
Author(s):  
Balaji Ommurugan ◽  
Amita Priya D ◽  
Navin Patil
Keyword(s):  
Hepatocellular Carcinoma ◽  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Drug Reactions ◽  
Endothelial Growth Factor ◽  
Carcinoma Renal Cell

ABSTRACTSorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Sorafenib acts by inhibiting various kinases like tyrosine kinase, RET tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis and cell proliferation. Acneiform eruptions are known side effect of EGFR inhibitors with incidence ranging between 20 to 90 percent [3], but acneiform eruptions with Sorafenib is seldom seen. Hence, we report a case of Sorafenib induced acneiform eruptions.Keywords: Sorafenib, EGFR, acneiform eruptions, adverse drug reactions

Sign in / Sign up

Export Citation Format

Share Document